Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ALLK | US
0.03
4.24%
Healthcare
Biotechnology
30/06/2024
16/10/2024
0.66
0.65
0.67
0.64
Allakos Inc. a clinical stage biopharmaceutical company develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy inflammatory and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002) which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease chronic urticaria severe allergic conjunctivitis and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition Allakos Inc. is conducting preclinical studies for AK007 which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos California.
View LessValue Stock (Price to Book < 3)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
81.6%1 month
81.8%3 months
88.2%6 months
90.1%-
-
0.69
0.47
0.25
-0.50
-
-
-182.51M
58.50M
58.50M
-
-
-
-
-121.54
5.71
3.18
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.11
Range1M
0.19
Range3M
0.42
Rel. volume
0.40
Price X volume
93.83K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
iShares MSCI Brazil ETF USD Acc | CSBR | Biotechnology | 4.56 | 61.99M | 0.44% | n/a | -2140.66% |
CELU | CELU | Biotechnology | 2.78 | 61.12M | -1.42% | n/a | 159.71% |
RAPT THERAPEUTICS INC. | RAPT | Biotechnology | 1.75 | 61.08M | -3.31% | n/a | 5.24% |
CEL-SCI Corporation | CVM | Biotechnology | 0.9852 | 60.58M | 2.88% | n/a | 143.19% |
Kronos Bio Inc | KRON | Biotechnology | 0.965 | 58.18M | 0.52% | n/a | 22.03% |
OncoCyte Corporation | OCX | Biotechnology | 3.11 | 53.22M | -0.32% | n/a | 16.15% |
Aadi Bioscience Inc | AADI | Biotechnology | 2.14 | 52.68M | 0.47% | n/a | 1.34% |
Actinium Pharmaceuticals Inc | ATNM | Biotechnology | 1.68 | 52.34M | -4.00% | n/a | 4.22% |
Affimed N.V | AFMD | Biotechnology | 3.33 | 52.22M | 6.56% | n/a | 0.00% |
Atara Biotherapeutics Inc | ATRA | Biotechnology | 9.2 | 52.20M | 9.79% | n/a | -81.03% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Beasley Broadcast Group Inc | BBGI | Broadcasting - Radio | 12.5 | 19.04M | 4.17% | n/a | 204.46% |
ILAG | ILAG | Building Products & Equipment | 1.02 | 18.42M | 2.01% | n/a | 5.48% |
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.6542 | 9.49M | -5.19% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2051 | 3.68M | -6.82% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.09 | 2.84M | -0.91% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.01 | 897.66K | -0.99% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.42 | 0 | 2.63% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.21 | 0 | 3.19% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.5 | 0 | 1.42% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.05 | 0 | 6.06% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.50 | 0.53 | Cheaper |
Ent. to Revenue | - | 4,005.99 | - |
PE Ratio | - | 40.42 | - |
Price to Book | 0.69 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 88.22 | 72.92 | Riskier |
Debt to Equity | 0.47 | -1.24 | Expensive |
Debt to Assets | 0.25 | 0.25 | Par |
Market Cap | 58.50M | 3.78B | Emerging |